Arixa Pharmaceuticals is developing oral antibiotics for resistant Gram-negative infections, an urgent need. The company's lead candidate, ARX-1796, is a proprietary orally available prodrug of Avibactam, a broad spectrum beta-lactamase inhibitor recently approved by the FDA. The company's technology platform applies unique prodrug chemistry to existing intravenous-only antimicrobial agents to allow their active ingredients to be orally administered. ARX-1796 is anticipated to enter Phase 1 clinical testing in 2019.
